𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

✍ Scribed by Wim K. Bleeker; Martin E. Munk; Wendy J. M. Mackus; Jeroen H. N. Van Den Brakel; Marielle Pluyter; Martin J. Glennie; Jan G. J. Van De Winkel; Paul W. H. I. Parren

Book ID
108675537
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
415 KB
Volume
140
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

In vitro and in vivo activity of MT201,
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
✍ Stefanie Naundorf; Susanne Preithner; Petra Mayer; Sandra Lippold; Andreas Wolf; πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 326 KB πŸ‘ 1 views

## Abstract In our study, a novel, fully human, recombinant monoclonal antibody of the IgG1 isotype, called MT201, was characterized for its binding properties, complement‐dependent (CDC) and antibody‐dependent cellular cytotoxicity (ADCC), as well as for its __in vivo__ antitumor activity in a nud

Phase I, double-blind, randomized, place
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease
✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 274 KB πŸ‘ 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub